Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
- 2018 (22) (remove)
Document Type
- Journal article (22) (remove)
Language
- English (22)
Keywords
- Positronen-Emissions-Tomografie (12)
- PET (10)
- positron emission tomography (8)
- neuroendocrine tumor (4)
- 18F-FDG (3)
- SPECT (3)
- theranostics (3)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 18F-LMI1195 (2)
Institute
- Klinik und Poliklinik für Nuklearmedizin (21)
- Medizinische Klinik und Poliklinik I (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Anatomie und Zellbiologie (2)
- Institut für Pharmakologie und Toxikologie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Neurologische Klinik und Poliklinik (1)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (10)
- Johns Hopkins University School of Medicine (4)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (1)
- Department of Nuclear Medicine, Kanazawa University (1)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (1)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (1)
- Johns Hopkins Medicine (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (1)
- Johns Hopkins University, Baltimore, MD, U.S. (1)
EU-Project number / Contract (GA) number
- 701983 (21)
As a scintigraphic approach evaluating cardiac nerve integrity, \(^{123}\)I-metaiodobenzylguanidine (123I-mIBG) has been recently Food and Drug Administration approved. A great deal of progress has been made by the prospective ADMIRE-HF trial, which primarily demonstrated the association of denervated myocardium assessed by \(^{123}\)I-mIBG and cardiac events. However, apart from risk stratification, myocardial nerve function evaluated by molecular imaging should also be expanded to other clinical contexts, in particular to guide the referring cardiologist in selecting appropriate candidates for specific therapeutic interventions. In the present issue of the Journal of Nuclear Cardiology, the use of 123I-mIBG for identifying cardiomyopathy patients, which would most likely not benefit from ICD due low risk of arrhythmias, is described. If we aim to deliver on the promise of cardiac innervation imaging as a powerful tool for risk stratification in a manner similar to nuclear oncology, studies such as the one reviewed here may imply an important step to lay the proper groundwork for a more widespread adoption in clinical practice.